Post Profile

A journalist on lessons from his Theranos takedown

Nick Bilton's analysis of his Theranos exposé shows how bad actors like Elizabeth Holmes can misuse employees and government regulators, but he is especially critical of access journalism practiced in the business trades. It's a great read for anyone who writes as part of their job. (more…)
read more

See more about: Elizabeth Holmes

Related Posts

Theranos Caves To Critics, Agrees To Release Data On Its Blood Tests

Business & Finance : Fast Company

Theranos CEO Elizabeth Holmes said the company will publish data disproving allegations made by the Wall Street Journal. After weathering a severe bout of bad press, medical startup Theranos is embracing transparency: On Monday, CEO...

Theranos founder Elizabeth Holmes slams WSJ story at newspaper event; publication responds

Technology : L.A. Times Tech Blog

Theranos founder Elizabeth Holmes vehemently disputed recent Wall Street Journal coverage about her health-technology start-up, saying at the WSJD tech conference that a recent article was erroneous, baseless and lacked context. "I ...

Theranos CEO Elizabeth Holmes Punches Back Against The Wall Street Journal

Business & Finance : Fast Company

Elizabeth Holmes defends Theranos against a scathing Wall Street Journal exposé—while speaking at a WSJ event. When Theranos founder Elizabeth Holmes agreed to be interviewed at the Wall Street Journal's WSJ.D Live conference here i...

Theranos CEO Elizabeth Holmes fires back at report attacking her company’s blood testing tech

Technology : Venture Beat

Elizabeth Holmes, the CEO of blood testing startup Theranos, has been in hot water since a scathing Wall Street Journal report about her company appeared last week. Today she was interviewed onstage at a WSJ conference, and gave her...

Under Fire, Theranos CEO Stifled Bad News

Technology : Tech -

Theranos CEO Elizabeth Holmes has continued to put a positive spin on her embattled blood-testing company—while broadly keeping employees in the dark on many issues—even as Theranos’s regulatory and legal troubles mount.


Copyright © 2016 Regator, LLC